Washington—Medical technology company Becton, Dickinson and Company (BD) has agreed to significantly expand its production in the United States through an investment package totaling $19 billion over the next few years.
Of the total amount, approximately $3 billion will be
allocated to expanding U.S. manufacturing facilities, with a significant
portion of that effort concentrated in Nebraska. The announcement was
highlighted by President Donald Trump, who linked it to his administration’s
tariff policy on medical devices.
Trump noted that over $1 billion will be allocated to
Nebraska to increase the manufacturing of various medical products, including
needles made with U.S.-produced steel. The company has facilities in Columbus
and Broken Bow, Nebraska, as well as production centers in other states.
BD announced that the agreement will allow it to increase
its domestic production of essential medical supplies by approximately 5
billion units per year, with the goal of having roughly 80% of the essential
consumables the company supplies in the United States come from domestic
production.
One of the most significant commitments is that 100% of BD
needles used in the United States will be manufactured domestically using
American steel. This measure is part of a strategy to reduce dependence on
foreign supply chains and strengthen the healthcare system's responsiveness.
Trump attributed the announcement to his tariff policy and
maintained that companies wishing to avoid these costs must increase their
production in the United States and hire local workers.